JOURNAL of
ONCOLOGICAL
SCIENCES

CASE REPORT

Deciphering the Role of Combination Therapy of Cobimetinib, Vemurafenib, and Antidepressant Drugs in QTc Prolongation and Torsade De Pointes (TDP) in Malignant Melanoma
Received Date : 22 Jan 2020
Accepted Date : 26 May 2020
Available Online : 24 Jun 2020
Doi: 10.37047/jos.2020-73730 - Article's Language: EN
J Oncol Sci.2020;6(2):123-6
This is an open access article under the CC BY-NC-ND license
ABSTRACT
Tyrosine kinase inhibitors (TKIs), particularly the combination of MEK inhibitors (cobimetinib and trametinib) and BRAF inhibitors (vemurafenib and dabrafenib), are now considered as the first-line treatment of patients with BRAF V600-mutated metastatic melanoma. Most cancer patients are on antidepressant drugs. In several case reports, vemurafenib has been reported for its adverse effects, such as nephrotoxic and cardiotoxic effects, including QTc prolongation. The antidepressant drugs, such as escitalopram and mirtazapine are also among the class of drugs that were reported to cause QTc prolongation and cardiac arrhythmias. This study is based on a patient with malignant melanoma and the investigation on combination therapy of vemurafenib, cobimetinib, and concomitant antidepressant drugs (escitalopram and mirtazapine). The patient had a history of recurrent syncope episodes, hypokalemia, QTc prolongation, and Torsades De Pointes (TDP). The drug therapy was discontinued, and intracardiac defibrillator (ICD) was implanted for patient’s safety. Furthermore, QTc prolongation and hypokalemia were persistent after drug discontinuation, indicating some degree of renal and/or cardiac injury. The patient was discharged on beta-blocker and potassium replacement therapy.
KAYNAKLAR
  1. Negulescu M, Deilhes F, Sibaud V, et al. Panniculitis associated with MEK inhibitor therapy: an uncommon adverse effect. Case Rep Dermatol. 2017;9(1):80‐85. [Crossref]  [PubMed]  [PMC] 
  2. Fiocchi R, Gori M, Taddei F, Trevisani L, Gallo M, Eleftheriou G. Cardiac toxicity of combined vemurafenib and cobimetinib administration. Int J Clin Pharmacol Ther. 2019;57(5):259‐263. [Crossref]  [PubMed] 
  3. Kloth JSL, Pagani A, Verboom MC, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015;112(6):1011‐1016. [Crossref]  [PubMed]  [PMC] 
  4. Launay-Vacher V, Zimner-Rapuch S, Poulalhon N, et al. Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer. 2014;120(14):2158‐2163. [Crossref]  [PubMed] 
  5. Teuma C, Pelletier S, Amini-Adl M, et al. Adjunction of a MEK inhibitor to vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury. Cancer Chemother Pharmacol. 2017;79(5):1043‐1049. [Crossref]  [PubMed] 
  6. Lieu CH, Hidalgo M, Berlin JD, et al. A Phase Ib dose-escalation study of the safety, tolerability, and pharmacokinetics of cobimetinib and duligotuzumab in patients with previously treated locally advanced or metastatic cancers with mutant KRAS. Oncologist. 2017;22(9):1024‐e1089. [Crossref]  [PubMed]  [PMC] 
  7. Sala M, Coppa F, Cappucciati C, et al. Antidepressants: their effects on cardiac channels, QT prolongation and torsade de pointes. Curr Opin Investig Drugs. 2006;7(3):256‐263. [PubMed] 
  8. Raftopoulos LG, Aggeli C, Zisimos K, et al. Cardiotoxicity after vemurafenib administration. Hellenic J Cardiol. 2019;60(4):256‐257. [Crossref]  [PubMed] 
  9. Jhaveri KD, Sakhiya V, Fishbane S. Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib. JAMA Oncol. 2015;1(8):1133‐1134. [Crossref]  [PubMed] 
  10. Cooke MJ, Waring WS. Citalopram and cardiac toxicity. Eur J Clin Pharmacol. 2013;69(4):755‐760. [Crossref]  [PubMed] 
  11. Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother. 2002;3(5):479‐498. [Crossref]  [PubMed]